Antech’s breakthrough cancer screening tool launches in Europe, supporting early canine cancer detection
2024年4月23日 - 3:00PM
ビジネスワイヤ(英語)
Antech, the veterinary diagnostics company focused on partnering
with veterinary professionals to predict, diagnose, and monitor
wellness and disease, today announced the launch of the
breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A
rapid, accurate, targeted cancer screening tool for high-risk
breeds and older dogs, Nu.Q® testing also includes prevalent types
of canine cancers, enabling veterinarians and pet owners to make
informed decisions about cancer care more quickly.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech,
part of Mars Science & Diagnostics said: “It’s exciting to
see innovations like Nu.Q® Canine Cancer Test become more widely
available to veterinary teams in Europe. With cancer affecting one
in four dogs1, it is critical that veterinary professionals have
access to fast and accurate cancer screening methods, so they can
make informed and timely decisions and ultimately change pet health
outcomes. This is what our work at Antech is all about.”
Nu.Q® Canine Cancer Test is a breakthrough technology
that measures circulating nucleosomes, supporting earlier cancer
detection in some of the most prevalent types of canine cancers.
Nu.Q® testing, run on the Element i+ analyser, is both
cost-effective and simple, requiring only 50µL of EDTA plasma from
a patient and providing accurate results in 5 to 10 minutes.
Studies2 have shown >75% detection rates for common cancers in
dogs like lymphoma and hemangiosarcoma when using Nu.Q®. As the
only patient-side in-house test that provides rapid and accurate
results from EDTA plasma, the Nu.Q® test is an aid to diagnosis
that can be run in clinic by veterinary professionals during annual
check-ups or regular senior wellness exams.
Dr. Maximiljan W. Krauss, Dipl. ECVS, Tierklink Düsseldorf, used Nu.Q®
Canine Cancer Test first-hand during the pilot phase and commented:
“At our clinic, we see around 1500 cases of cancer in dogs a year.
Lymphoma and hemangiosarcoma are the most common type of cancer we
see affecting dogs as young as five years old. Thanks to Nu.Q®
Canine Cancer Test and the Element i+ in-house analyzer, we have a
fast and accurate means to screen for cancer, which helps us
intervene early and choose the best possible care pathway for every
patient. At the end of the day, early interventions can make a real
difference to a dog’s quality of life and the time they have to
spend with their family.”
Nu.Q® is a registered trademark of VolitionRx Limited and its
subsidiaries. The Nu.Q® Canine Cancer Test is supplied under
license by Belgian Volition SRL.
Nu.Q® will be available in the UK as part of the European
launch. For orders and more information about the product, please
contact Antech UK.
About Mars Science & Diagnostics and Antech
Mars Science & Diagnostics is a division of Mars Petcare, a
diverse business dedicated to one purpose: A BETTER WORLD FOR
PETS™. Science & Diagnostics brings together the power of
leading pet health science with expertise across diagnostics, data,
and technology to improve outcomes in pet health. Our veterinary
diagnostics business, Antech, spans in-house diagnostic laboratory
instruments and consumables, including rapid assay diagnostic
products and digital cytology services; local and cloud-based data
services; practice information management software and related
software and support; 90+ reference laboratories around the globe;
veterinary imaging and technology; education; and board-certified
specialist support services. Our at-home diagnostics offering
includes Wisdom Panel™ DNA test products, the world’s most accurate
pet DNA test. For 60 years, our Waltham Petcare Science Institute
has been advancing science to better understand pet health.
1
https://www.avma.org/resources/pet-owners/petcare/cancer-pets#:~:text=Approximately%201%20in%204%20dogs,rate%20of%20cancer%20in%20cats.
2 Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation
of plasma nucleosome concentrations in dogs with a variety of
common cancers and in healthy dogs. BMC Vet Res 18, 329
(2022). https://doi.org/10.1186/s12917-022-03429-8
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240422725707/en/
Media Contact for Antech Queries: Géraldine Varoqui
Geraldine.Varoqui@effem.com Media Contact for Volition
Queries: +44 (0)7557 774620 mediarelations@volition.com